Immune Responses in Patients with Inflammatory Bowel Disease after Vaccination
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Clinical Immunology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 102
Special Issue Editors
Interests: clinical infectiology (opportunistic infections, HIV, viral hepatitis, mycobacterioses, gastrointestinal infections); chronic inflammatory bowel diseases
2. Department for Gastroenterology, Hepatology and Transplant Medicine, University Hospital Essen, 45147 Essen, Germany
Interests: inflammatory bowel disease; opportunistic infections
Special Issue Information
Dear Colleagues,
We are pleased to invite you to publish your work in this Special Issue, ‘Immune Responses in Patients with Inflammatory Bowel Disease after Vaccination’. Patients with inflammatory bowel disease often require immunomodulatory therapies to control their symptoms and intestinal inflammation. To date, numerous drugs from different drug classes have been approved. Combination therapies are being increasingly discussed for refractory IBD courses. Immunomodulation potentially leads to a restricted immune response after application of vaccines in these patients. As a result, the protective effect of vaccines against infections and severe disease progression may be reduced. In addition, the risk of opportunistic infections and severe courses of conventional infections increases, particularly with combined immunomodulatory therapy.
This Special Issue aims to gather important insights into the immune response to vaccination in patients with inflammatory bowel disease. Both original research articles and reviews are welcome. Research areas may include (but not limited to) basic scientific findings on vaccination from the fields of virology, bacteriology and immunology, innovative approaches to vaccine development and clinical studies on vaccine response and disease progression in IBD patients. Of particular interest are the approaches to prevent opportunistic infections such as cytomegalovirus reactivation.
We look forward to receiving your contributions.
Dr. Phil-Robin TepasseDr. Arne Bokemeyer
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammatory bowel disease
- vaccination
- opportunistic infections
- immune response
- immunomodulatory therapy
